OTCM
PBLA
Market cap53kUSD
Jul 07, Last price
0.01USD
1D
0.00%
1Q
117.65%
IPO
-100.00%
Name
Panbela Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
180.33%
Rev. gr., 5y
%
Revenues
0k
Net income
-25m
L-27.68%
CFO
-25m
L+65.29%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Panbela Therapeutics, Inc. is a biopharmaceutical enterprise currently in clinical development, along with its subsidiaries, dedicated to advancing innovative therapies for cancer patients. The company's therapeutic endeavors primarily target pancreatic disorders, including pancreatitis, pancreatic cancer, and neoadjuvant pancreatic cancer. Beyond pancreatic diseases, they are also exploring treatments for colorectal cancer, ovarian cancer, and various other oncology indications. Their flagship experimental drug, SBP-101, is currently undergoing Phase Ia/Ib clinical trials, specifically intended for individuals diagnosed with metastatic pancreatic ductal adenocarcinoma. Established in 2011, the company, headquartered in Waconia, Minnesota, rebranded from its prior name, Sun BioPharma, Inc., to Panbela Therapeutics, Inc. in December 2020.
IPO date
Jul 29, 2014
Employees
6
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||